These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 20512088)

  • 21. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004).
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):195-201. PubMed ID: 16105564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Surveillance of antimicrobial resistance among nosocomial gram-negative pathogens from 15 teaching hospitals in China in 2005].
    Yang QW; Xu YC; Chen MJ; Hu YJ; Ni YX; Sun JY; Yu YS; Kong HS; He L; Wu WY; Ye HF; Yang YM; Zhu LN; Guo SH; Ji P; Zhu ZH; Ren JK; Zhang LX; Sun ZY; Zhu XH; Tong MQ; Zhao WS; Mei YN; Liu Y; Zhang ZJ; Duan Q; Li D; Liu PP; Wang J; Han LX; Wang H; Xie XL
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2753-8. PubMed ID: 18167265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Susceptibility to tigecycline of isolates from samples collected in hospitalized patients with secondary peritonitis undergoing surgery.
    Tubau F; Liñares J; Rodríguez MD; Cercenado E; Aldea MJ; González-Romo F; Torroba L; Berdonces P; Plazas J; Aguilar L; Delgado A; García-Escribano N;
    Diagn Microbiol Infect Dis; 2010 Mar; 66(3):308-13. PubMed ID: 20022193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resistance of Klebsiella pneumoniae strains producing and not producing ESBL (extended-spectrum beta-lactamase) type enzymes to selected non-beta-lactam antibiotics.
    Sekowska A; Janicka G; Kłyszejko C; Wojda M; Wróblewski M; Szymankiewicz M
    Med Sci Monit; 2002 Mar; 8(3):BR100-4. PubMed ID: 11889457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline.
    Garau J
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():198-202. PubMed ID: 18154548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regional variations in multidrug resistance among Enterobacteriaceae in the USA and comparative activity of tigecycline, a new glycylcycline antimicrobial.
    DiPersio JR; Dowzicky MJ
    Int J Antimicrob Agents; 2007 May; 29(5):518-27. PubMed ID: 17376657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study.
    Betriu C; Rodríguez-Avial I; Gómez M; Culebras E; López F; Alvarez J; Picazo JJ;
    Diagn Microbiol Infect Dis; 2006 Dec; 56(4):437-44. PubMed ID: 16949245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Time-kill synergy tests of tigecycline combined with imipenem, amikacin, and ciprofloxacin against clinical isolates of multidrug-resistant Klebsiella pneumoniae and Escherichia coli.
    Yim H; Woo H; Song W; Park MJ; Kim HS; Lee KM; Hur J; Park MS
    Ann Clin Lab Sci; 2011; 41(1):39-43. PubMed ID: 21325253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tigecycline in vitro activity against gram-negative and gram-positive pathogens collected in Italy.
    Roveta S; Marchese A; Debbia EA
    Chemotherapy; 2008; 54(1):43-9. PubMed ID: 18073470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tigecycline: a novel broad-spectrum antimicrobial.
    Slover CM; Rodvold KA; Danziger LH
    Ann Pharmacother; 2007 Jun; 41(6):965-72. PubMed ID: 17519296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of porin loss on the activity of tigecycline against Klebsiella pneumoniae producing extended-spectrum beta-lactamases or plasmid-mediated AmpC-type beta-lactamases.
    Conejo MC; Hernández JR; Pascual A
    Diagn Microbiol Infect Dis; 2008 Jul; 61(3):343-5. PubMed ID: 18339509
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro activity of tigecycline against 2423 clinical isolates and comparison of the available interpretation breakpoints.
    Papaparaskevas J; Tzouvelekis LS; Tsakris A; Pittaras TE; Legakis NJ;
    Diagn Microbiol Infect Dis; 2010 Feb; 66(2):187-94. PubMed ID: 19836184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tigecycline: in-vitro performance as a predictor of clinical efficacy.
    Hawkey P; Finch R
    Clin Microbiol Infect; 2007 Apr; 13(4):354-62. PubMed ID: 17359318
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae.
    Daly MW; Riddle DJ; Ledeboer NA; Dunne WM; Ritchie DJ
    Pharmacotherapy; 2007 Jul; 27(7):1052-7. PubMed ID: 17594211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activity of tigecycline and comparators against skin and skin structure pathogens: global results of the Tigecycline evaluation and surveillance trial, 2004-2009.
    Namdari H; Tan TY; Dowzicky MJ
    Int J Infect Dis; 2012 Jan; 16(1):e60-6. PubMed ID: 22104303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prevalence of extended-spectrum beta-lactamases in nosocomial Escherichia coli and Klebsiella spp. strains isolated from blood cultures].
    Zarakolu P; Metan G; Hasçelik G; Akova M
    Mikrobiyol Bul; 2007 Oct; 41(4):579-84. PubMed ID: 18173077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phenotypic confirmation of extended-spectrum B-lactamases (ESBL) in clinical isolates of Escherichia coli and Klebsiella pneumoniae at the San Juan Veterans Affairs Medical Center.
    Del Carmen Rodríguez M; Vera DE; Ramírez-Ronda CH; Saavedra S
    P R Health Sci J; 2004 Sep; 23(3):207-15. PubMed ID: 15631176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model.
    Zhanel GG; Baudry PJ; Tailor F; Cox L; Hoban DJ; Karlowsky JA
    J Antimicrob Chemother; 2009 Oct; 64(4):824-8. PubMed ID: 19643776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
    Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
    Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.